Oncology Roadmap:

Brand Spending Benchmarks and Market Forecast to 2013

Publication Date	January 2009
Publisher	Cutting Edge Information
Product Type	Report
Pages
ISBN Number	not applicable
Product Code	CUT00075

Buy this product or for assistance call +44 20 7060 7474

PDF £6,010.00$9997 | €6727

PRINT £7,210.00$11993 | €8070

FAX Order above formats by FAX

Summary

This report entails comprehensive forecasts and detailed Budget Benchmarks.
Cutting Edge Information's new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match.

Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever.
At the same time, brand budget benchmarks reveal spending in key areas throughout development and launch.

Uncover Oncology Threats and Opportunities - Equip your teams with the most comprehensive forecast of the oncology marketplace - from today's stalwarts to tomorrow's blockbusters. Track real brand spending from the pre-clinical period through the first year on the market. Benchmarks include advertising and promotion, medical affairs, decision support (market research) and market access.

The report analyzes oncology portfolios from the following major companies:

Amgen / AstraZeneca
Bristol-Myers Squibb /Celgene
Eli Lilly/ GlaxoSmithKline
Johnson & Johnson/ Merck
Novartis/ Pfizer
Roche and Genentech / Sanofi-Aventis
Schering-Plough

Content

Brand Spending Benchmarks
- Average brand spending by budget category:
  - Advertising and promotion
  - Medical affairs
  - Decision support (market research)
  - Market access
- Average brand spending by development stage:
  - Pre-Clinical tphase
  - Phase 3a
  - Phase 3b
  - First year on the market
Product Profiles by Class
- Brand Information
  - Brand and generic name
  - Drug class
  - Delivery mechanism
  - Line of treatment
- Sales Data
  - Historical/current sales
  - Forecasted sales
- Approved Indications
- Current Product Development Phases
- Competitive and Strategic Positioning
- Market Opportunities and Brand Growth
- Patent, Generic and Litigation Information
Oncology Indication Analysis
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
- Major market events, changes in treatments, patent expirations, etc.
Companies' Oncology Portfolios
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status